DEXCOM INC — Director's Dealing 2019

Mar 12, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2019-03-08

Reporting Person: Murphy Patrick Michael (SVP Legal Affairs)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-08	Common Stock	S	400	$141.56	Disposed	28908	Direct
2019-03-08	Common Stock	A	11714	$0.001	Acquired	40622	Direct

Footnotes

F1: On June 15, 2018, Mr. Murphy adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Murphy. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2: Included in this number are 26,711 unvested restricted stock units, 11,714 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 11,210 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 3,787 of which were granted on March 8, 2017 and shall vest through March 8, 2020.

F3: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.